Hyperkalemia due to topical timolol for hemangioma

Affiliations

¹ College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
² College of Medicine, Imam Mohammad bin Saud University, Riyadh, Saudi Arabia.
³ Division of Dermatology, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia.

Case Reports

Bushra Alasmari et al. JAAD Case Rep. 2023.

. 2023 Jul 17:39:53-54.

doi: 10.1016/j.jdcr.2023.07.006. eCollection 2023 Sep.

¹ College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
² College of Medicine, Imam Mohammad bin Saud University, Riyadh, Saudi Arabia.
³ Division of Dermatology, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia.

No abstract available

Keywords: adverse effect; hemangioma; hyperkalemia; timolol.

Conflict of interest statement

None disclosed.

1. Munden A., Butschek R., Tom W.L., et al. Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies. Br J Dermatol. 2014;170(4):907–913. - PMC - PubMed
1. Lin Z., Zhang B., Yu Z., Li H. The effectiveness and safety of topical β-receptor blocker in treating superficial infantile haemangiomas: a meta-analysis including 20 studies. Br J Clin Pharmacol. 2020;86(2):199–209. doi: 10.1111/bcp.14196. - DOI - PMC - PubMed
1. Swenson E.R. Severe hyperkalemia as a complication of timolol, a topically applied ß-adrenergic antagonist. Arch Intern Med. 1986;146(6):1220–1221. - PubMed
1. Pandhi D., Jakhar D., Tandon A., Singal A. Topical timolol in PHACES syndrome: is it safe? Indian J Dermatol Venereol Leprol. 2018;84(4):488–491. - PubMed
1. Guo S., Ni N. Topical treatment for capillary hemangioma of the Eyelid using β-blocker solution. Arch Ophthalmol. 2010;128(2):255–256. - PubMed